Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC).

Author:

Finn Richard S.1,Ryoo Baek-Yeol2,Merle Philippe3,Kudo Masatoshi4,Bouattour Mohamed5,Lim Ho-Yeong6,Breder Valeriy Vladimirovich7,Edeline Julien8,Chao Yee9,Ogasawara Sadahisa10,Yau Thomas11,Garrido Marcelo12,Chan Stephen Lam13,Knox Jennifer J.14,Daniele Bruno15,Ebbinghaus Scot16,Chen Erluo16,Siegel Abby B.16,Zhu Andrew X.17,Cheng Ann-Lii18,

Affiliation:

1. University of California, Los Angeles, Los Angeles, CA;

2. Asan Medical Center, Seoul, South Korea;

3. Lyon University, Lyon, France;

4. Kindai University, Faculty of Medicine, Osaka, Japan;

5. Service d’Oncologie Medicale, APHP, Clichy, France;

6. Samsung Medical Center, Seoul, South Korea;

7. Russian Oncological Research Center N.N. Blokhin of Ministry of Health, Moscow, Russian Federation;

8. Centre Eugene Marquis, Rennes, France;

9. Taipei Veterans General Hospital, Taipei, Taiwan;

10. Chiba University Graduate School of Medicine, Chiba, Japan;

11. The University at Hong Kong, Hong Kong, China;

12. Pontificia Universidad Católica de Chile, Santiago, Chile;

13. State Key Laboratory in Oncology of South China, The Chinese University of Hong Kong, Shatin, Hong Kong;

14. Princess Margaret Cancer Centre and University of Toronto, Toronto, ON, Canada;

15. Ospedale del Mare, Napoli, Italy;

16. Merck & Co., Inc., Kenilworth, NJ;

17. Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA;

18. National Taiwan University Hospital, Taipei, Taiwan;

Abstract

4004 Background: Pembro received accelerated approval based on results of KEYNOTE-224, a phase 2 trial in pts with advanced HCC in the second line setting. KEYNOTE-240 (NCT02702401) was a randomized, placebo (Pbo) controlled, phase 3 study of Pembro vs BSC in pts with previously treated advanced HCC. Methods: Eligible pts had a radiographic or pathologic diagnosis of HCC, radiographic progression on/intolerance to sorafenib, Child-Pugh A disease and ECOG PS 0-1. Pts were randomized 2:1 to receive Pembro 200 mg + BSC or Pbo + BSC IV every 3 wk, stratified by geographic region, macrovascular invasion and ɑ-fetoprotein levels for ≤35 cycles or until confirmed PD/unacceptable toxicity. Response was assessed every 6 wk per RECIST v1.1 by central imaging review. Co-primary endpoints were OS and PFS. Secondary endpoints included ORR, DOR and safety. Data cutoff was Jan 2 2019 for OS; Mar 26 2018 for PFS and ORR. Results: 413 patients were randomized; 278 to Pembro and 135 to Pbo. After a median follow up of 13.8 mo, 10.1% of pts remained on Pembro and 3.0% on Pbo. Pembro improved OS (HR: 0.78; one sided p = 0.0238) and PFS (HR: 0.78; one sided p = 0.0209) vs Pbo; these differences did not meet significance per the prespecified statistical plan. ORR was 16.9% (95% CI 12.7-21.8%) for Pembro vs 2.2% (95% CI 0.5-6.4%) for Pbo (nominal one sided p = 0.00001); responses on Pembro were durable (median DOR: 13.8 mo [1.5-23.6+]). Off study, new therapy use was 42% for Pembro and 47% for Pbo. The safety profile including incidence of hepatitis and other immune mediated events was generally consistent with that previously reported in Pembro studies; no cases of HBV/HCV flare were identified. Conclusions: Pembro reduced the risk of death by 22% and improved PFS over Pbo in pts with advanced HCC, although significance was not reached per prespecified statistical criteria. ORR in the Pembro arm was consistent with that of KEYNOTE-224. Subsequent anticancer therapy in the Pbo arm likely impacted the OS results. The safety profile was comparable to that established for Pembro monotherapy. These results are overall consistent with those of KEYNOTE-224 further supporting second line therapy with Pembro in HCC pts. Clinical trial information: NCT02702401.

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3